Efficiency of different strategies to detect autoantibodies to extractable nuclear antigens

Journal of Immunological Methods

Volumn 360, Issue 1-2, 2010, Pages 89-95

  Almeida González, Delia ^a   Cabrera de León, Antonio ^a,b,c   Rodríguez Pérez, María del Cristo ^a   Brito Díaz, Buenaventura ^a   González Hernández, Ana ^a,c   García García, Diego ^a   Vázquez Moncholi, Carmen ^a   Aguirre Jaime, Armando ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c Madrid Spain   (Spain)

Author keywords

Algorithms; Antinuclear antibodies; Cost effectiveness; Diagnostic tests; Efficiency; Extractable nuclear antigen

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; EXTRACTABLE NUCLEAR ANTIGEN ANTIBODY; UNCLASSIFIED DRUG; ANTI-EXTRACTABLE NUCLEAR ANTIGEN ANTIBODIES; CELL NUCLEUS ANTIGEN; EPITOPE;

ALGORITHM; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; COST EFFECTIVENESS ANALYSIS; DOUBLE IMMUNODIFFUSION; FLUOROENZYMEIMMUNOASSAY; HUMAN; IMMUNOASSAY; IMMUNODIFFUSION; IMMUNOFLUORESCENCE; INTERMETHOD COMPARISON; LINE IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; BLOOD; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; MASS SCREENING; METABOLISM; TUMOR CELL LINE;

ALGORITHMS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, NUCLEAR; CELL LINE, TUMOR; COST-BENEFIT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNODIFFUSION; MULTIPHASIC SCREENING; SEROEPIDEMIOLOGIC STUDIES;

EID: 77955711393     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.06.013     Document Type: Article

References (26)

1. Bizzaro N., Tozzoli R., Tonutti E., Piazza A., Manoni F., Ghirardello A., et al. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. J. Immunol. Meth. 1998, 219:99. (PubMed: 9831391).
2. Bonaguri C., Melegari A., Dall'Aglio P., Ballabio A., Terenziani P., Russo A., Battistelli L., Aloe R., Camisa R., Campaniello G., Sartori E., Monica C. An Italian multicenter study for application of a diagnostic algorithm in autoantibody testing. Ann. N.Y. Acad. Sci. 2009, 1173:124. (PubMed: 19758140).
3. Bunn C., Kveder T. Counterimmunoelectrophoresis and immunodiffusion for the detection of antibodies to soluble cellular antigens. Manual of Biological Markers of Disease 1993, 1. Kluwer Academic Publishers, Dordrecht, The Netherlands, A3. W.J. Van Venrooij, R.N. Maini (Eds.).
4. Clark G., Reichlin M., Tomasi T.B. Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. J. Immunol. 1969, 102:117. (PubMed: 4179557).
5. Eissfeller P., Sticherling M., Scholz D., Hennig K., Lüttich T., Motz M., Kromminga A. Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases. Ann. N.Y. Acad. Sci. 2005, 1050:327. (PubMed: 16014549).
6. Hoffman I.E., Peene I., Veys E.M., De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin. Chem. 2002, 48:2171. (PubMed: 12446473).
7. Homburger H.A. Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin. Proc. 1995, 70:183. (PubMed: 7845044).
8. López-Hoyos M., Rodríguez-Valverde V., Martinez-Taboada V. Performance of antinuclear antibody connective tissue disease screen. Ann. N.Y. Acad. Sci. 2007, 1109:322. (PubMed: 17785321).
9. Meheus L., Van Venrooij W.J., Wiik A., Charles P.J., Tzioufas A.G., Meyer O., et al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin. Exp. Rheumatol. 1999, 17:205. (PubMed: 10342047).
10. Miescher P., Fauconnet M. Absorption of L. E. factor by isolated cell nuclei. Experientia 1954, 10:252. (PubMed: 13183062).
11. Phan T.G., Ng W.W., Bird D., Smithers K., Wong V., Gallagher K., et al. High-quality, cost-effective strategy for detection of autoantibodies to extractable nuclear antigens. Clin. Diagn. Lab. Immunol. 2001, 8:471. (PubMed: 11329442).
12. Pottel H., Wiik A., Locht H., Gordon T., Roberts-Thomson P., Abraham D., et al. Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders. Clin. Exp. Rheumatol. 2004, 22:579. (PubMed: 15485011).
13. Rondeel J.M., van Gelder W., van der Leeden H., Dinkelaar R.B. Different strategies in the laboratory diagnosis of autoimmune disease: immunofluorescence, enzyme-linked immunosorbent assay or both?. Ann. Clin. Biochem. 1999, 36:189. (PubMed: 10370735).
14. Rouquette A.M., Desgruelles C., Laroche P. Evaluation of the new multiplexed immunoassay, FIDIS, for simultaneous quantitative determination of antinuclear antibodies and comparison with conventional methods. Am. J. Clin. Pathol. 2003, 120:676. (PubMed: 14608892).
15. Solomon D.H., Kavanaugh A.J., Schur P.H., American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002, 47:434. (PubMed: 12209492).
16. Tampoia M., Fontana A., Di Serio F., Maggiolini P., Pansini N. Application of a diagnostic algorithm in autoantibody testing: assessment of clinical effectiveness and economic efficiency. Clin. Chim. Acta 2003, 333:181. (PubMed: 12849902).
17. Tampoia M., Brescia V., Fontana A., Zucano A., Morrone L.F., Pansini N. Application of a combined protocol for rational request and utilization of antibody assays improves clinical diagnostic efficacy in autoimmune rheumatic disease. Arch. Pathol. Lab. Med. 2007, 131:112. (PubMed: 17227110).
18. Tan E.M., Kunkel H.G. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J. Immunol. 1966, 96:464. (PubMed: 16424153).
19. Tan E.M., Feltkamp T.E., Smolen J.S., Butcher B., Dawkins R., Fritzler M.J., et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997, 40:1601. (PubMed: 9324014).
20. Tozzoli R., Bizzaro N., Tonutti E., Villalta D., Bassetti D., Manoni F., et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am. J. Clin. Pathol. 2002, 117:316. (PubMed: 11863229).
21. United Kingdom National External Quality Assessment Service. (Accessed March 2010). http://www.ukneqas.org.uk.
22. Van Venrooij W.J., Charles P., Maini R.N. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J. Immunol. Meth. 1991, 140:181. (PubMed: 1906075).
23. Vercammen M., Meirlaen P., Sennesael J., Velkeniers B., T 'Kint S., Verbruggen L., et al. Diagnostic accuracy of the FIDIS multiplex fluorescent microsphere immunodetection system for anti-extractable nuclear antigen (ENA) antibodies in connective tissue diseases. Clin. Chem. Lab. Med. 2007, 45:505. (PubMed: 17439329).
24. Von Mühlen C.A., Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin. Arthritis Rheum. 1995, 24:323. (PubMed: 7783073).
25. Vos P.A., Bast E.J., Derksen R.H. Cost-effective detection of non-antidouble-stranded DNA antinuclear antibody specificities in daily clinical practice. Rheumatology (Oxford) 2006, 45:629. (PubMed: 16368728).
26. Weller T.H., Coons A.H. Fluorescent antibody studies with agents of varicella and herpes zoster propagated in vitro. Proc. Soc. Exp. Biol. Med. 1954, 86:789. (PubMed: 13204357).